Clinical Trials Logo

DIPG clinical trials

View clinical trials related to DIPG.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04295759 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

Start date: July 27, 2020
Phase: Phase 1
Study type: Interventional

This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.

NCT ID: NCT03478462 Active, not recruiting - Neuroblastoma Clinical Trials

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

CLOVER-2
Start date: April 30, 2019
Phase: Phase 1
Study type: Interventional

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.

NCT ID: NCT01952769 Active, not recruiting - DIPG Clinical Trials

Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma

Start date: February 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Diffuse pontine gliomas are incurable with currently used treatments. based on data stating that progressive tumors inhibit immune system, would try to enhance immune system activity and tumor cell killing. anti PD1 prevents one of the important mechanisms allowing the tumor to supress the immune system thus we hope it will allow for prolonged control of the tumors